Patent ID: 8628775
Filing Date: 2014-01-14
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method of delaying the onset of or reducing a T cell-mediated immune response in an individual, the method comprising: selecting an individual diagnosed as having or as being at risk of acquiring a condition characterized by an excessive or unwanted T cell-mediated immune response; and administering to the individual an anti-Fc antibody, and a multimeric compound that binds to at least two P-Selectin Glycoprotein Ligand 1 (PSGL-1) proteins on the surface of a T cell, wherein the multimeric compound comprises two polypeptide chains, each of the polypeptide chains comprising (i) a binding domain that binds to PSGL-1, wherein the binding domain comprises a P-Selectin extracellular domain or a PSGL-1-binding fragment thereof; or wherein the binding domain comprises an E-Selectin extracellular domain or a PSGL-1-binding fragment thereof, and (ii) a heterologous amino acid sequence, wherein the heterologous amino acid sequence comprises an immunoglobulin heavy chain constant region, and wherein the polypeptide chains are linked via the heterologous amino acid sequence to form the multimeric compound, wherein the binding of the multimeric compound to the at least two PSGL-1 proteins on the surface of the T cell induces a signal transduction pathway that results in the death of the T cell, thereby delaying the onset of or reducing a T cell-mediated immune response in the individual.